1378038-47-1

Upstream product

• 1378040-17-5 (6-(1-Hydroxyethyl)-pyrimidin-4-yl)-carbamic acid tert-butyl ester 
• 1378039-25-8 2-(2,6-dichlorophenyl)-2H-pyrazolo[4,3-c]pyridine 5-oxide 
• 1378039-24-7 2-(2,6-dichlorophenyl)-2H-pyrazolo[4,3-c]pyridine 
• 1378039-23-6 [1-(4-azidopyridin-3-yl)meth-(E)-ylidene]-(2,6-dichlorophenyl)amine 
• 1378039-22-5 4-azidonicotinaldehyde 
• 1378039-53-2 (6-formylpyrimidin-4-yl)bis-carbamic acid tert-butyl ester 
• 1378040-18-6 1-(6-aminopyrimidin-4-yl)-ethanol 
• 1378039-20-3 4-chloro-2-(2,6-dichlorophenyl)-2H-pyrazolo[4,3-c]pyridine 
• 153034-90-3 2-Chloro-4-iodo-3-pyridinecarboxaldehyde 
• 871836-51-0 4-chloro-1H-pyrazolo [4,3-c]pyridine 
• 114077-82-6 4-chloronicotinaldehyde 

Relevant academic research and scientific papers

PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDINES AND THEIR USE AS TYK2 INHIBITORS

The invention provides compounds of Formula (I), stereoisomers or pharmaceutically acceptable salts thereof, wherein A, X, R1, R2, R4 and R5 are defined herein, a pharmaceutical composition that includes a compound of Formula (I) and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of using the compound or composition in therapy, as TYK2 Kinase inhibitors.